Our management team co-founded or first funded twelve startups that each grew to valuations exceeding $1 billion. More are on the way.
Chairman
Kevin Kimberlin
Kevin Kimberlin has co-founded or backed ventures that helped shape modern communications, biotechnology, and medicine. He co-founded Ciena Corporation with Dr. David Huber to commercialize the first dense wavelength division multiplexing system, the foundation of today’s high-capacity fiber-optic networks. Earlier, he provided the capital structure that enabled Millicom, the FCC-selected cellular partner, to form Racal-Millicom, which became Vodafone.
In the life sciences, Mr. Kimberlin co-founded Immune Response Corporation with Dr. Jonas Salk to develop the first FDA-approved cancer vaccine. He also helped found Myriad Genetics, the first human-genome company, known for discovering the BRCA1 breast-cancer gene, and supported Osiris Therapeutics, which achieved the world’s first regulatory approval for a stem-cell-based therapy.
Through Spencer Trask, he continues to invest in companies with the potential to transform industries and improve human health. Beyond his business work, Mr. Kimberlin supports environmental, educational, and cultural initiatives, including long-standing commitments to the Audubon Society and Yaddo, the artist community. He earned his MBA from Harvard Business School.

